Boston Scientific Co. (NYSE:BSX) Stock Position Raised by BNP PARIBAS ASSET MANAGEMENT Holding S.A.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 4.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,119,399 shares of the medical equipment provider's stock after acquiring an additional 173,034 shares during the quarter. Boston Scientific accounts for 0.9% of BNP PARIBAS ASSET MANAGEMENT Holding S.A.'s portfolio, making the stock its 17th largest holding. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned 0.28% of Boston Scientific worth $345,205,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Capital World Investors boosted its position in shares of Boston Scientific by 69.9% in the first quarter. Capital World Investors now owns 16,008,085 shares of the medical equipment provider's stock worth $1,096,394,000 after buying an additional 6,588,256 shares during the period. Marshall Wace LLP boosted its position in shares of Boston Scientific by 115.9% in the second quarter. Marshall Wace LLP now owns 6,720,480 shares of the medical equipment provider's stock worth $517,544,000 after buying an additional 3,608,158 shares during the period. Capital Research Global Investors acquired a new stake in shares of Boston Scientific in the first quarter worth $182,897,000. AustralianSuper Pty Ltd boosted its position in shares of Boston Scientific by 4,292.3% in the third quarter. AustralianSuper Pty Ltd now owns 2,676,847 shares of the medical equipment provider's stock worth $224,320,000 after buying an additional 2,615,903 shares during the period. Finally, Ameriprise Financial Inc. boosted its position in shares of Boston Scientific by 30.0% in the second quarter. Ameriprise Financial Inc. now owns 7,899,610 shares of the medical equipment provider's stock worth $608,349,000 after buying an additional 1,824,405 shares during the period. 89.07% of the stock is owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the company's stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total value of $570,511.10. Following the completion of the transaction, the executive vice president now owns 37,468 shares of the company's stock, valued at $3,061,135.60. This represents a 15.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Michael F. Mahoney sold 162,777 shares of the company's stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $84.63, for a total value of $13,775,817.51. Following the completion of the transaction, the chief executive officer now directly owns 1,572,096 shares of the company's stock, valued at approximately $133,046,484.48. This trade represents a 9.38 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 309,270 shares of company stock valued at $26,196,718 in the last quarter. Corporate insiders own 0.50% of the company's stock.

Analyst Ratings Changes

Several analysts have recently commented on the company. Citigroup raised their target price on Boston Scientific from $92.00 to $98.00 and gave the stock a "buy" rating in a research report on Thursday, October 24th. BTIG Research increased their price objective on Boston Scientific from $84.00 to $93.00 and gave the stock a "buy" rating in a report on Monday, October 14th. JPMorgan Chase & Co. increased their price objective on Boston Scientific from $82.00 to $85.00 and gave the stock an "overweight" rating in a report on Thursday, July 25th. Canaccord Genuity Group increased their price objective on Boston Scientific from $88.00 to $98.00 and gave the stock a "buy" rating in a report on Monday, October 21st. Finally, Barclays increased their price objective on Boston Scientific from $78.00 to $86.00 and gave the stock an "overweight" rating in a report on Thursday, August 22nd. Four investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $93.39.

Boston Scientific Price Performance

NYSE BSX opened at $90.17 on Thursday. Boston Scientific Co. has a twelve month low of $53.93 and a twelve month high of $91.08. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The stock has a market capitalization of $132.90 billion, a PE ratio of 74.52, a P/E/G ratio of 2.56 and a beta of 0.79. The stock has a 50-day simple moving average of $85.71 and a 200 day simple moving average of $79.92.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The business had revenue of $4.21 billion during the quarter, compared to analysts' expectations of $4.04 billion. During the same quarter in the previous year, the firm earned $0.50 EPS. The firm's revenue was up 19.3% compared to the same quarter last year. Research analysts anticipate that Boston Scientific Co. will post 2.46 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.